CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Lundbeck

HLUYY
N/A

Next catalyst

Phase 3Q3 2027

Eptinezumab

Chronic Migraine in Children

Get an email about HLUYY's next catalysts

Track Lundbeck (HLUYY) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 1 more upcoming event in our data (Phase 2 readout).See the timeline

Catalyst Timeline

2 upcoming, 0 past

Phase 3Next

Eptinezumab Phase 3 Est. Readout (PROSPECT-1)

Q3 2027~QEptinezumab315

Primary completion for Eptinezumab trial (NCT05897320) in Episodic Migraine

Source
Phase 2

Lu AG13909 Phase 2 Est. Readout (BalanCeD)

Q3 2027~QLu AG1390916

Estimated primary completion for Lu AG13909 trial (NCT06471829) in Cushing's Disease. Topline data typically follows completion by weeks to months.

Source

Market Overview

Stock performance and key metrics

NASDAQHealthcare🇺🇸North America
Drug Pipeline

Nalmefene

Phase 3

Alcohol Dependence

Idalopirdine

Phase 3

Alzheimer's Disease

Vortioxetine

Phase 3

Depressive Disorder, Major

Lu AF35700

Phase 3

Schizophrenia

Clobazam Low Dose

Phase 3

Epilepsy

Lu AA21004

Phase 3

Generalized Anxiety Disorder

Venlafaxine extended release

Phase 3

Major Depressive Disorder

MK0928, gaboxadol/Duration of Treatment - 1 year

Phase 3

Insomnia

Azilect®

Phase 3

Parkinson's Disease

Bendamustine at a

Phase 3

Indolent Non-Hodgkin's Lymphoma

Agomelatine

Phase 3

Major Depressive Disorder

Escitalopram

Phase 3

Major Depressive Disorder

Bupropion XL

Phase 3

Depression

Clobazam High Dose

Phase 3

Epilepsy

Lu AF82422

Phase 3

Multiple System Atrophy

Desmoteplase

Phase 3

Acute Ischemic Stroke

Adjunct brexpiprazole

Phase 3

Major Depression Disorder

ADT

Phase 3

Major Depressive Disorder

Sertindole

Phase 3

Schizophrenia

Intravenous Carbamazepine (IV CBZ)

Phase 3

Epilepsy

Brexpiprazole

Phase 3

Schizophrenia

MK0928, gaboxadol

Phase 3

Insomnia

Vortioxetine (Lu AA21004)

Phase 3

Major Depressive Disorder

Clobazam Medium Dose

Phase 3

Epilepsy

Clobazam

Phase 3

Lennox-Gastaut Syndrome

gaboxadol

Phase 3

Insomnia

rasagiline

Phase 3

Parkinson's Disease

Eptinezumab

Phase 3

Chronic Migraine in Children

Zicronapine

Phase 3

Schizophrenia

Lu AG09222

Phase 2

Migraine

Bifeprunox

Phase 2

Bipolar I Disorder

Lu AE58054

Phase 2

Schizophrenia

Lu AG13909

Phase 2

Congenital Adrenal Hyperplasia

Lu AA24493

Phase 2

Friedreich's Ataxia

Venlafaxine XL

Phase 2

Major Depressive Disorder

Methylprednisoloneacetate

Phase 2

Knee Joint Osteoarthrosis

Erythropoietin

Phase 2

Bipolar Disorder

Melperone HCl

Phase 2

Parkinson's Disease

Vortioxetine (tablet)

Phase 2

Depressive Disorder, Major

Zicronapine open-label lead-in

Phase 2

Schizophrenia

Vortioxetine (IV)

Phase 2

Depressive Disorder, Major

Lu AA24530

Phase 2

Major Depressive Disorder

Frequently asked questions

What is in Lundbeck's drug pipeline?→

CatalystAlert tracks 42 drug candidates in Lundbeck's (HLUYY) pipeline across Phase 3, Phase 2. Its lead program is Eptinezumab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Lundbeck's next FDA catalyst?→

Lundbeck's (HLUYY) next tracked catalyst is a Phase 3 readout expected Q3 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track HLUYY biotech catalysts?→

Add HLUYY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Lundbeck's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply